ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Health Technology

Trans Genic Inc.

Business Summary

Trans Genic Inc. engages in the development, distribution, and licensing of genetically engineered animals and antibodies. It operates through the following segments: Contract Research Organization (CRO), Diagnostic Analysis, and Trans Genic Business Service (TGBS). The CRO segment deals with clinical trials, pharmacological tests, pharmacokinetic tests, non-clinical trials, and the production of genetically modified mice. The Diagnostic Analysis segment provides pathological diagnosis, gene analysis, and drug discovery support services for personalized medicine. The TGBS segment offers advice and support services related to the promotion of new business through mergers and acquisitions, business succession, and business revitalization. The company was founded on April 21, 1998 and is headquartered in Kumamoto, Japan.

Financial Highlights

Mar 2021 JPYUSD
Gross Profit2,777.10M26.18M
Operating income895.64M8.44M
Income before tax695.20M6.55M
Net income546.28M5.15M
Diluted EPS31.450.29
Dividends Per Share30.02
Total Assets8,928.90M80.80M
Total liabilities3,892.00M35.22M
Total equity4,916.45M44.49M
Operating cash flow1,222.36M11.52M
Currency in JPYCurrency in USD

Historical Data

 Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021
Revenue 2,302.90M 3,601.28M 8,674.50M 11,046.67M 11,046.13M
Gross Profit 748.93M 822.45M 1,498.44M 1,779.72M 2,777.10M
Operating income 153.94M 60.55M 270.06M 62.70M 895.64M
Income before tax 81.93M 14.45M 202.87M -249.65M 695.20M
Net income 80.69M 20.89M 202.21M -440.71M 546.28M
EBITDA 266.39M 204.45M 460.51M 292.68M 1,147.11M
Diluted EPS 5.62 1.39 11.90 -25.37 31.45
Dividends Per Share 0 0 0 0 3
Total Assets 3,902.42M 5,934.68M 6,475.27M 7,571.68M 8,928.90M
Total liabilities 729.09M 1,592.85M 1,588.53M 3,154.97M 3,892.00M
Total equity 3,173.32M 4,341.82M 4,886.74M 4,416.61M 4,916.45M
Operating cash flow 232.81M 219.05M 147.69M -20.98M 1,222.36M
 Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021
Revenue 21.26M 32.49M 78.22M 101.60M 104.15M
Gross Profit 6.91M 7.42M 13.51M 16.36M 26.18M
Operating income 1.42M 0.54M 2.43M 0.57M 8.44M
Income before tax 0.75M 0.13M 1.82M -2.29M 6.55M
Net income 0.74M 0.18M 1.82M -4.05M 5.15M
EBITDA 2.46M 1.84M 4.15M 2.69M 10.81M
Diluted EPS 0.05 0.01 0.10 -0.23 0.29
Dividends Per Share 0 0 0 0 0.02
Total Assets 35.02M 55.80M 58.50M 70.13M 80.80M
Total liabilities 6.54M 14.97M 14.35M 29.22M 35.22M
Total equity 28.47M 40.82M 44.15M 40.91M 44.49M
Operating cash flow 2.14M 1.97M 1.33M -0.19M 11.52M

Valuation Measures

Mar 2021
Operating margin8.10%
Profit margin4.94%

Key executives

  • Director, Manager-Finance & Accounting: Kazuo Watanabe
  • Director & Chief Technology Officer: Kenichi Yamamura
  • Director, Manager-Personnel & General Affairs: Yutaka Funabashi
  • Director & GM-Contract Research Organization: Shunichi Kitajima


  • Trans Genic Inc. (3.1%)
  • FUJII MASAKI (0.9%)
  • Mutoh Co., Ltd. (0.9%)
  • Limousine International KK (0.8%)
  • HARADA IKUO (0.7%)
  • Dimensional Fund Advisors LP (0.6%)
  • Dimensional Fund Advisors Ltd. (0.0%)

Contact Details

Related Companies

  • LunaPath LLC
  • Kizuki Corp.
  • Galax Corp.
  • Medicinal Chemistry Pharmaceutical Co. Ltd.
  • TG Business Service Inc.
  • New Drug Research Center Inc.
  • GP Biosciences Ltd. /Genetic Analysis Business/
  • Primmune Inc


    Last Updated on 16 May, 2022

    Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

    Celebrate our next chapter
    Free access for everyone - Sep. 30

    Find out more